Inovio Q4 net loss $54.5M; VGX-3100 Phase 3 trial fails primary endpoint in biomarker group

INOVIO PHARMACEUTICALS, INC.

2022-FY EPS reported -$1.17 revenue$10,262,268

Net loss of $54.5M ($0.22 per share) for Q4 2022; full year net loss $279.8M ($1.17 per share).
Cash and short-term investments $253M as of Dec 31, 2022; cash runway projected into Q1 2025.
REVEAL2 Phase 3 trial of VGX-3100 did not meet primary endpoint in biomarker-selected population (p=0.115); but achieved statistical significance in all-participants population (p=0.001).
Positive Phase 1/2 data for INO-3107 in RRP: median decrease of 3 surgical interventions; 91% of patients saw reduction.
Positive Phase 1b data for INO-4201 as Ebola booster: 100% of treated participants boosted humoral responses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INOVIO PHARMACEUTICALS, INC. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 1, 2023, Inovio Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-056363

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.